title: The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.
abstract: Complete surgical excision at an early stage remains the only curative treatment for cutaneous melanoma with few available adjuvant therapy options. Nevertheless, melanoma is a relatively immunogenic tumor type and particularly amenable to immunotherapeutic approaches. A dense network of cutaneous dendritic cells (DC) may account for the reported efficacy of vaccination through the skin and provide an attractive target for the immunotherapy of melanoma. Several phenotypically distinct DC subsets are discernable in the skin, among others, epidermal Langerhans cells and dermal DC. Upon appropriate activation both subsets can efficiently migrate to melanoma-draining lymph nodes (LN) to prime T cell-mediated responses. Unfortunately, from an early stage, melanoma development is characterized by strong immune suppression, facilitating unchecked tumor growth and spread. Particularly the primary tumor site and the first-line tumor-draining LN, the so-called sentinel LN, bear the brunt of this melanoma-induced immune suppression-and these are exactly the sites where anti-melanoma effector T cell responses should be primed by DC in order to prevent early metastasis. Through local immunopotentiation or through DC-targeted vaccination, the dermis may be utilized as a portal to activate DC and kick-start or boost effective T cell-mediated anti-melanoma immunity, even in the face of this immune suppression.
authors.affiliation: Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
authors.forename: D
authors.initials: D
authors.lastname: Oosterhoff
authors.forename: B J R
authors.initials: BJ
authors.lastname: Sluijter
authors.forename: B N
authors.initials: BN
authors.lastname: Hangalapura
authors.forename: T D
authors.initials: TD
authors.lastname: de Gruijl
mesh_terms: D015703:Antigens, CD / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D019070:Cell Lineage / Q000276:immunology; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis; D020405:Dermis / Q000166:cytology / Q000276:immunology*; D006801:Humans; D007109:Immunity; D007167:Immunotherapy / Q000379:methods; D007271:Injections, Intradermal; D007801:Langerhans Cells / Q000166:cytology / Q000276:immunology*; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy; D058990:Molecular Targeted Therapy / Q000379:methods*; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination / Q000379:methods*
chemical_list: D015703:Antigens, CD; D019496:Cancer Vaccines; D016207:Cytokines